Sutro Biopharma (NASDAQ:STRO) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.6, a high estimate of $17.00, and a low estimate of $12.00. This current average has decreased by 4.23% from the previous average price target of $14.20.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Sutro Biopharma's perception among financial...
Login or create a forever free account to read this news
Sign up/Log in
